Novavax Inc (NVAX) — closed signal from May 4, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on August 2, 2026 — -10.6% at the close.
Predicted vs. what happened
What happened
Reached its target in 3 days.
The thesis — published May 4, 2026
Speculative biotech position with recent shifts toward licensing and royalty deals backed by ties to Sanofi and Pfizer. Upcoming earnings and later vaccine trial data will drive sentiment. The company has some financial flexibility, but unclear near-term sales and high short interest make the stock volatile; gains could be sharp but downside risk is meaningful.
Primary drivers
- Shifting to licensing could reduce how much cash is needed to run the business
- Relationships with Sanofi and Pfizer add meaningful strategic options
- Near-term earnings will likely change how investors view the stock
- Large short interest and event risk increase the chance of big swings
How it played out
NVAX: target reached in 3 days, gains later reversed
Lyra published a speculative short-term thesis at $8.19, with expected growth of 22% and a $9.99 target. The thesis pointed to licensing and royalty deals, relationships with Sanofi and Pfizer, upcoming earnings, financial flexibility, high short interest, and event risk.
NVAX reached the target in 3 days. It rose to $11.61 on May 27, a peak gain of 41.7%. The stock later fell and ended the window at $7.32, below the publication price. The thesis played out within the window, but the gain did not hold.
What happened during the window
On May 6, 2026, Novavax reported first-quarter revenue of $140 million. It also said licensing, royalties, and other revenue included $30 million from its Pfizer agreement.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.